Depression events associated with proton-pump inhibitors in postmarketing drug surveillance data
Makunts, T.; Joulfayan, H.; Ta, K.; Abagyan, R.
Show abstract
Proton-pump inhibitors, PPIs, are widely prescribed and are available over the counter for prolonged reduction of stomach acid production and related disorders. PPIs irreversibly inhibit the hydrogen/potassium ATPase in gastric parietal cells. Recent retrospective studies have described an association between PPI use and depression. However, there is conflicting evidence that PPI therapy improves depressive symptoms. Considering the widespread use and over the counter availability of these drugs, further investigation into depression adverse event was warranted with a larger scale postmarketing set of reports. Here we analyzed over 68,178 reports from the FDA Adverse Event Reporting System consisting of PPI and histamine-2 receptor antagonist monotherapy records and found a statistically significant association between use of PPIs and depression. Additionally, we analyzed each of the six currently marketed PPIs individually and observed the association with the depression adverse reaction for all of them.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real-world observation on response to cholinesterase inhibitors or selective serotonin reuptake inhibitors prescribed to outpatients with dementia using electronic medical records 92%
- Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial 90%
- Near, far, wherever you are: Phenotype-related variation in pharmacogenomic effect sizes across the psychiatric drug literature. 89%
Similar papers in this journal
- People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study 93%
- Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults 91%
- Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study 90%
Similar papers in this journal
- DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19 92%
- Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition 91%
- Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study 90%
Similar papers in this journal
- Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study 94%
- Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation 93%
- Association between Psychotropic Medications Functionally Inhibiting Acid Sphingomyelinase and reduced risk of Intubation or Death among Individuals with Mental Disorder and Severe COVID-19: an Observational Study 93%
Similar papers in this journal
- Unveiling the Hidden Toll of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System 93%
- Sales of over-the-counter products containing codeine in 31 countries, 2013-2019: a retrospective observational study 91%
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.